SIIRD provides funding up to US$1M for joint R&D projects between companies based in Singapore and Israel. Interested companies are welcome to apply for this funding by following the instructions in the Proposal Submission page. For projects approved after May 2017, the grant disbursements to Singapore and Israeli companies would be in local currency i.e. Singapore Dollars and Israeli Shekels respectively.
Who can apply?
The application must be jointly submitted by a Singapore-registered company and an Israel-registered company. Either company must not have more than 20% shareholding in the partnering company. The joint project must be undertaken in Singapore and Israel. At least 30% of the actual R&D work must be done in Singapore as well as in Israel. Technology and product developed must have potential for commercialization.
Since June 2011, the SIIRD programme has been broadened to include non-commercial Research and Development entities in Singapore (A*STAR research institutes, R&D entities in the Universities, Polytechnics, etc.).
The SIIRD team is open to discussions with non-government and non-profit organizations which possess R&D capabilities and are keen to participate in the SIIRD programme. The SIIRD team is also open to discussions with interested companies whose proposal ideas may not initially fit SIIRD's funding framework.
How does SIIRD funding work?
The submitted proposals will be subjected to evaluations by independent professionals from Singapore and Israel, after which the evaluated proposals will be submitted to SIIRD Board for approval. SIIRD Board convenes at least twice a year. For the latest submission deadline for proposals, please refer to the News and Calendar.
Find out more about the proposal submission process at the Proposal Submission page.
Benefits of Utilizing SIIRD Funding
- SIIRD shares companies' risk from R&D projects
- SIIRD does not take equity in the funded companies
- SIIRD does not share Intellectual Property Rights of developed products/technologies
- SIIRD does not require collateral from the funded companies
Should the innovation or technology developed in whole or part during the SIIRD project be successfully commercialized by product sales or licensing of the innovation or technology, SIIRD is entitled to repayment of up to 100% of the SIIRD funding or Conditional Grant. All repayments to SIIRD are considered as pre–tax expenses. Repayment shall be based on either of the following:
1. The Conditional Grant shall be repaid, until 100% of the Conditional Grant has been repaid, at the rate of:
- Product sales - 2.5% of Gross Sales
- Licensing of innovation or technology – 30% of payments under such license agreement(s)
2. When the following maximum percentages of the Conditional Grant have been repaid in any of the following years following the first commercial transaction, no additional payments to SIIRD on account of the Conditional Grant shall be required.
|Years Following Completion Date
||Maximum Percentage of Conditional Grant and Other Sums to Be Repaid
|6 or more
After the fifth anniversary of the completion dateof the project,companies could submit a formal request to SIIRD, with supporting documents, for their repayment obligation to be reviewed for cases where the innovation/technology has failed, reached its end of life or is discontinued.